He Jiang, Liu Guozheng, Gupta Suresh, Zhang Yumin, Rusckowski Mary, Hnatowich Donald J
Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
J Nucl Med. 2004 Jun;45(6):1087-95.
Conventional nuclear medicine imaging with large radiolabeled molecules such as antitumor antibodies suffers from slow localization and clearance. Pretargeting is under active investigation as an alternative using either (strept)avidin/biotin, bispecific antibodies, or oligomers. However, only the use of oligomers such as phosphorodiamidate morpholinos (MORFs) in pretargeting offers the potential of signal amplification at the target. Amplification targeting is a multistep procedure with the potential to greatly improve target localization of radioactivity (and eventually drugs) through the intermediate use of polymers conjugated with multiple copies of oligomers.
This study was conducted to prove the concept in vivo in tumored mice of amplfication targeting.
Nude mice bearing LS174T tumors received in order: the anti-CEA antibody MN14 conjugated with MORF, a polymer conjugated with multiple copies of complementary MORFs (cMORFs), and, finally, (99m)Tc-MORF.
In tumored animals, dual radiolabels ((99m)Tc and (111)In) were used to demonstrate that, after 18 h, about 25% of antibody MORFs in tumor were targeted with polymeric cMORFs and, after 3 h, about 12% of the polymeric cMORFs in tumor were targeted with (99m)Tc-MORF. Therefore, hybridization in tumor in both cases (i.e., polymeric cMORF to antibody MORF and radiolabeled MORF to polymeric cMORF) was surprisingly efficient given the barriers to targeting in vivo and the competition between targeting and clearance. Moles of radiolabeled MORF accumulating in tumor were more than tripled for study animals receiving all 3 injections compared with control animals not receiving the antibody or the polymer. Furthermore, MORF expression (on antibody) and cMORF expression (on polymer) were rapidly lost in normal organs such as liver, spleen, and kidneys but not in tumor, thus improving the target-to-nontarget ratios.
Although signal amplification has not yet been convincingly demonstrated and amplification targeting will require further studies for optimization, the concept has now been shown to be feasible.
使用大型放射性标记分子(如抗肿瘤抗体)进行的传统核医学成像存在定位和清除缓慢的问题。预靶向作为一种替代方法正在积极研究中,可使用(链霉)抗生物素蛋白/生物素、双特异性抗体或寡聚物。然而,只有在预靶向中使用诸如吗啉代磷二酰胺(MORF)等寡聚物才具有在靶标处信号放大的潜力。放大靶向是一个多步骤过程,有可能通过中间使用与多个寡聚物拷贝缀合的聚合物来极大地改善放射性(最终是药物)的靶标定位。
本研究旨在在荷瘤小鼠体内验证放大靶向的概念。
携带LS174T肿瘤的裸鼠依次接受:与MORF缀合的抗CEA抗体MN14、与多个互补MORF(cMORF)拷贝缀合的聚合物,最后是(99m)Tc-MORF。
在荷瘤动物中,使用双放射性标记((99m)Tc和(111)In)证明,18小时后,肿瘤中约25%的抗体MORF被聚合物cMORF靶向,3小时后,肿瘤中约12%的聚合物cMORF被(99m)Tc-MORF靶向。因此,考虑到体内靶向的障碍以及靶向与清除之间的竞争,在两种情况下(即聚合物cMORF与抗体MORF以及放射性标记的MORF与聚合物cMORF)肿瘤中的杂交效率惊人。与未接受抗体或聚合物的对照动物相比,接受所有3次注射的研究动物肿瘤中积累的放射性标记MORF的摩尔数增加了两倍多。此外,MORF(在抗体上)和cMORF(在聚合物上)的表达在肝脏、脾脏和肾脏等正常器官中迅速消失,但在肿瘤中没有,从而提高了靶标与非靶标的比率。
虽然尚未令人信服地证明信号放大,并且放大靶向需要进一步研究以进行优化,但现在已证明该概念是可行的。